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participate.Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in
Patients Undergoing Percutaneous Coronary Interventions: Insights From the
NCDR Cath-PCI Registry1Thomas T. Tsai, Uptal D. Patel, Tara I. Chang, Kevin F. Kennedy,
Frederick A. Masoudi, Michael E. Matheny, Mikhail Kosiborod, Amit P. Amin,
John C. Messenger, John S. Rumsfeld, John A. Spertus
Acute kidney injury (AKI) is a serious and potentially preventable complication
of percutaneous coronary interventions (PCIs) that is associated with adverse
outcomes. In a cohort of 985,737 consecutive patients who underwent PCI, 69,658
patients (7.1%) experienced AKI, with 3,005 (0.3%) requiring new dialysis. The
factors most strongly associated with AKI included ST-segment elevation
myocardial infarction, severe chronic kidney disease, and cardiogenic shock. The in-
hospital mortality rate was 9.7% for patients with AKI and 34% for those requiring
dialysis. Deﬁning strategies to minimize the risk of AKI in patients undergoing
a PCI are needed to improve the safety and outcomes of the procedure.The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization:
First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus Uncoated
Balloon Angioplasty10Dierk Scheinert, Stephan Duda, Thomas Zeller, Hans Krankenberg, Jens Ricke,
Marc Bosiers, Gunnar Tepe, Scott Naisbitt, Kenneth Rosenﬁeld
Percutaneous treatments of peripheral vascular disease are associated with frequent
restenosis. Paclitaxel-coated balloons deliver an antirestenotic agent without the
need for a stent scaffold. The LEVANT I trial was a prospective, randomized
controlled human study of 101 patients that compared angiographic and clinical
outcomes for treatment of femoropopliteal artery disease with the Lutonix drug-
coated balloons (DCB) versus uncoated balloon (control). The primary endpoint of
late lumen loss at 6 months was 0.46  1.13 mm for the Lutonix DCB group
compared with 1.09  1.07 mm for the control group; p ¼ 0.016. Treatment with
the Lutonix DCB reduced late lumen loss with safety comparable to that of control
angioplasty through 24 months.JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.(continued on A-20)
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A-20Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal
Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary
Intervention: A Pre-Speciﬁed Analysis From the PRODIGY Study (PROlonging Dual
Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY)20Marco Valgimigli, Matteo Tebaldi, Marco Borghesi, Pascal Vranckx, Gianluca Campo,
Carlo Tumscitz, Elisa Cangiano, Monica Minarelli, Antonella Scalone, Caterina Cavazza,
Jlenia Marchesini, Giovanni Parrinello, for the PRODIGY Investigators
We randomized 2,013 patients to bare-metal stents (BMS), zotarolimus-eluting
Endeavor Sprint stents (Medtronic Cardiovascular, Santa Rosa, California) (ZES-
S), paclitaxel-eluting stents (PES), or everolimus-eluting stents (EES). The rate of
major adverse cardiac events was lowest in the EES group (19.2%; 95% conﬁdence
interval [CI]: 16% to 22.8%), highest in the BMS group (32.1%; 95% CI: 28.1% to
36.3%), and intermediate in the PES (26.2%; 95% CI: 22.5% to 30.2%) and ZES-S
(27.8%; 95% CI: 24.1% to 31.9%) groups (chi-square ¼ 18.9, p ¼ 0.00029). The 2-
year incidence of stent thrombosis in the EES group (1%) was similar to that in the
ZES-S group (1.4%), whereas it was lower compared with the PES (4.6%) and
BMS (3.6%) groups (chi-square ¼ 16.9, p ¼ 0.0001). In our study, EES out-
performed BMS with respect to both efﬁcacy and safety endpoints.
See additional content in the online version of this issue.Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome
After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary
Artery Disease29Klaus Tiroch, Julinda Mehilli, Robert A. Byrne, Stefanie Schulz, Steffen Massberg,
Karl-Ludwig Laugwitz, Marc Vorpahl, Melchior Seyfarth, Adnan Kastrati, for the ISAR-LEFT
MAIN Study Investigators
We evaluated the impact of anatomic and procedural variables on the 3-year outcome
of the unprotected left main coronary artery (uLMCA) itself after drug-eluting stent
implantation, based on a randomized study of 607 patients. The 3-year mortality
rate was 5.8%, and the TLR rate was 12.5%; 235 (39%) patients had true bifurcation
lesion (TBL). TBL was associated with more stents and was a predictor of in-stent
restenosis (ISR) and target lesion revascularization (TLR). Multiple-stent implan-
tation was a predictor of ISR. Culotte stenting showed better results compared with
T-stenting for ISR. The overall SYNTAX score had an impact on uLMCA-TLR. In
the multivariate analysis, independent predictors for TLR were TBL, age, and
EuroSCORE (European System for Cardiac Operative Risk Evaluation).EDITORIAL COMMENTEvolving Concepts in the Management of Left Main Coronary Disease 37Marie-Claude Morice(continued on A-21)
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A-21Initial Success Rate of Percutaneous Coronary Intervention for Chronic Total
Occlusion in a Native Coronary Artery Is Decreased in Patients Who Underwent
Previous Coronary Artery Bypass Graft Surgery39Tomohiko Teramoto, Etsuo Tsuchikane, Hitoshi Matsuo, Yoriyasu Suzuki, Tsuyoshi Ito,
Tatsuya Ito, Maoto Habara, Kenya Nasu, Masashi Kimura, Yoshihisa Kinoshita,
Mitsuyasu Terashima, Yasushi Asakura, Tetsuo Matsubara, Takahiko Suzuki
Although revascularization of chronic total occlusion (CTO) in a native coronary
artery (NCA) by percutaneous coronary intervention (PCI) is an effective option for
ameliorating angina in patients with bypass graft failure, its success rate is lower
than that of CTO-PCI in an NCA without previous coronary artery bypass grafting
(CABG). The anatomic complexity and unstable hemodynamic state were unfa-
vorable conditions for novel wiring techniques. This study indicates that more
profound tactics and skills are needed for the revascularization of CTO in NCA in
patients with previous CABG.Periprocedural Myocardial Injury in Chronic Total Occlusion Percutaneous
Interventions: A Systematic Cardiac Biomarker Evaluation Study47Nathan Lo, Tesfaldet T. Michael, Danyaal Moin, Vishal G. Patel, Mohammed Alomar,
Aristotelis Papayannis,DaishaCipher, ShuaibM.Abdullah, Subhash Banerjee,Emmanouil S. Brilakis
We examined 325 consecutive chronic total occlusion percutaneous coronary
interventions (PCI) performed at our institution to evaluate the incidence, corre-
lates, and clinical outcomes of periprocedural myocardial injury (PMI). All patients
had creatine kinase-myocardial band and troponin measured before PCI and 8 to 12
and 18 to 24 h after PCI. PMI was deﬁned as creatine kinase-myocardial band
3 the upper limit of normal. PMI occurred in 8.6% of patients, was more
common in patients treated with retrograde than antegrade approach (13.8% vs.
6.7%, p ¼ 0.04), and was associated with higher incidence of major adverse cardiac
events during a median follow-up of 2.3 years.(continued on A-22)
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A-22Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients
With Acute ST-Segment Elevation Myocardial Infarction: A Pooled Analysis of the
EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial
INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an
Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial
Infarction) Trials55Manel Sabaté, Lorenz Räber, Dik Heg, Salvatore Brugaletta, Henning Kelbaek,
Angel Cequier, Miodrag Ostojic, Andrés Iñiguez, David Tüller, Antonio Serra,
Andreas Baumbach, Clemens von Birgelen, Rosana Hernandez-Antolin, Marco Rofﬁ,
Vicente Mainar, Marco Valgimigli, Patrick W. Serruys, Peter Jüni, Stephan Windecker
No data are available on the safety and efﬁcacy of newer-generation drug-eluting
stents (DES) compared with bare-metal stents (BMS) in an appropriately powered
population of ST-segment elevation myocardial infarction (STEMI) patients. The
present analysis, pooling the data from 2 major randomized trials, comparing
second-generation DES (everolimus-eluting and biolimus A9-eluting stents) with
BMS in an all-comer STEMI patients, showed that newer-generation DES are
able to reduce patient-oriented endpoint (composite of all-cause death, any
myocardial infarction, and any revascularization) compared with BMS at 1-year
follow-up, mainly driven by a lower risk of target lesion revascularization, target
vessel reinfarction, and deﬁnite stent thrombosis.
See additional content in the online version of this issue.The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents
in ST-Segment Elevation Myocardial Infarction): 2-Year Results From a Multicenter
Randomized Controlled Trial64Manel Sabaté, Salvatore Brugaletta, Angel Cequier, Andrés Iñiguez, Antonio Serra,
Rosana Hernádez-Antolín, Vicente Mainar, Marco Valgimigli, Maurizio Tespili,
Pieter den Heijer, Armando Bethencourt, Nicolás Vázquez, Bianca Backx, Patrick W. Serruys
We sought to assess the 2-year outcomes of the EXAMINATION (Everolimus-
Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial
Infarction) trial that compared the performance of everolimus-eluting stents (EES)
versus bare-metal stents (BMS) in an ST-segment elevation myocardial infarction
(STEMI) population. A total of 1,498 patients were randomized to receive EES
(n ¼ 751) or BMS (n ¼ 747). At 2 years, both rates of target lesion revasculari-
zation and deﬁnite and deﬁnite or probable stent thrombosis were signiﬁcantly
lower in the EES group than in the BMS group. In conclusion, the 2-year follow-
up of the EXAMINATION trial conﬁrmed the safety and efﬁcacy of EES
compared with BMS in the setting of STEMI.(continued on A-23)
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A-23A Novel Noninvasive Technology for Treatment Planning Using Virtual Coronary
Stenting and Computed Tomography-Derived Computed Fractional Flow Reserve72Kyung-Hee Kim, Joon-Hyung Doh, Bon-Kwon Koo, James K. Min, Andrejs Erglis,
Han-Mo Yang, Kyung-Woo Park, Hae-Young Lee, Hyun-Jae Kang, Yong-Jin Kim,
Sung Yun Lee, Hyo-Soo Kim
This study was performed to determine the feasibility of treatment planning using
virtual coronary stenting and computed tomography–derived computed fractional
ﬂow reserve (FFRCT). Post-virtual stenting FFRCT was computed in 48 lesions and
was compared with FFR after stent implantation. FFR after stenting and FFRCT
after virtual stenting were 0.90  0.05 and 0.88  0.05, respectively. The mean
difference between FFRCT and FFR was 0.024. Diagnostic accuracy of FFRCT to
predict residual ischemia after stenting was 96%. This novel technology using virtual
coronary stenting and FFRCT may be useful in planning the treatment strategy
before the invasive procedures in patients with coronary artery disease.EDITORIAL COMMENTDeﬁning the Flow-Limiting Stenosis Noninvasively for Management of Patients
With Coronary Artery Disease79Tiago A. Magalhães, João A. C. LimaThe Absorb Bioresorbable Vascular Scaffold in Coronary Bifurcations:
Insights From Bench Testing81Vladimír Dzavík, Antonio Colombo
The authors conducted a series of experiments of bifurcation stenting with theAbsorb
bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, California) (BVS) in
a plastic in vitro bifurcation model, using commonly used simple and complex
bifurcation techniques. The authors demonstrated the feasibility of re-crossing the
struts of the BVS deployed in themain vessel and dilating these with a balloon inﬂated
across the side-branch ostium. The authors also demonstrated the feasibility of per-
forming low-pressure ﬁnal kissing balloon inﬂations when the combined diameter of
the 2 balloons is below the recommendedmaximal diameter of the BVS, as calculated
by Finet’s law.
See additional content in the online version of this issue.A Next-Generation Bioresorbable Coronary Scaffold System: From Bench to First
Clinical Evaluation: 6- and 12-Month Clinical and Multimodality Imaging Results89Stefan Verheye, John A. Ormiston, James Stewart, Mark Webster, Elias Sanidas, Ricardo Costa,
J. Ribamar Costa, Jr., Daniel Chamie, Andrea S. Abizaid, Ibraim Pinto, Lynn Morrison,
Sara Toyloy, Vinayak Bhat, John Yan, Alexandre Abizaid
The DESolve First-in-Man trial assessing the DESolve Bioresorbable Coronary
Scaffold demonstrated no scaffold thrombosis and no major adverse cardiac events
directly attributable to the scaffold at 12 months. At 6 months, in-scaffold late lumen
loss (by quantitative coronary angiography) was 0.19  0.19 mm; neointimal volume
(by intravascular ultrasound) was 7.19 3.56%, without evidence of scaffold recoil or
late malapposition. Effectiveness ﬁndings were conﬁrmed by optical coherence
tomography showing uniform, thin neointimal coverage (0.12 0.04mm)of the struts
and by multislice computed tomography at 12 months, which demonstrated excellent
vessel patency. These results prompt further study of this novel device in larger studies.(continued on A-24)
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A-24IMAGES IN
INTERVENTIONShort- and Long-Term Implications of a Bioresorbable Vascular Scaffold Implantation
on the Local Endothelial Shear Stress Patterns100Christos V. Bourantas, Michail I. Papafaklis, Hector M. Garcia-Garcia, Vasim Farooq,
Roberto Diletti, Takashi Muramatsu, Yaojun Zhang, Fanis G. Kalatzis, Katerina K. Naka,
Dimitrios I. Fotiadis, Yoshinobu Onuma, Lampros K. Michalis, Patrick W. SerruysThree-Dimensional Optical Coherence Tomography for Guidance of Complex
Percutaneous Coronary Interventions102Jurgen M. R. Ligthart, Roberto Diletti, Karen Witberg, Carl SchultzMassive Coronary Aneurysm After Multiple Percutaneous Interventions:
An Iatrogenic or Unpreventable Disaster?104Wei-Ting Chang, Cheng-Han Lee
This article has accompanying videos that can be viewed in the online version
of this issue.Anomalous Right Coronary Artery From the Proximal
Left Anterior Descending Artery: A Rare Finding and its Clinical Signiﬁcancee1Arun Kannan, John PaulowskiPrimary Percutaneous Intervention in a Patient With Anterior
and Inferior Wall Myocardial Infarction Because of a Rare Coronary Artery
Anomalye3Mohit D. Gupta, Girish MP, Bhagya N. Pandit, Sanjay Tyagi
ONLINE FEATURES
These articles do not appear in the printed issue. They are available in the
online versions of this issue.(continued on A-25)
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A-25CORRESPONDENCE
Research
CorrespondencePersistent High Residual Shunt Rate 2 Years After Patent Foramen Ovale Closure
Using a Bioabsorbable Device106Roel J. R. Snijder, Martijn C. Post, Thijs B. J. M. Mulder, Ben J. Van den Branden,
Juriën M. Ten Berg, Maarten J. SuttorpLetters to
the EditorP2Y12-Based Platelet Function Assays Should be Complemented With
Cyclooxygenase-Dependent Testing in Framing the Therapeutic Windows
for Dual Antiplatelet Therapy107Hrvoje Gasparovic, Mate PetricevicREPLYThomas Cuisset, Jacques Quilici, Jean-Louis Bonnet, Marie-Christine AlessiLooking for the Native Annulus After Transcatheter Aortic Valve Replacement? 108Jérôme CaudronREPLYJonathon Leipsic, Ronald K. Binder, John G. WebbIs Time of Renal Hypoperfusion an Important Variable in Determining Response to
Renal Artery Revascularization?110Ruihai Zhou, George A. StoufferEDITOR’S PAGE The “Chicken Little” of Renal Stent Trials: The CORAL Trial in Perspective 111Christopher J. White
